Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid β peptide (1-42) interaction

Journal of Neuroscience Research

Volumn 80, Issue 6, 2005, Pages 877-886

  Phu, Mai Jane ^a   Hawbecker, Sharon K ^a   Narayanaswami, Vasanthy ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

AEDANS; Amyloid peptide; Apolipoprotein E Alzheimer's disease; Fluorescence; Fluorescence resonance energy; Oligomerization; Quenching; Transfer; Tryptophan

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; CYSTEINE; ETHYLENEDIAMINE DERIVATIVE; N (IODOACETYL) N' (5 SULFO 1 NAPHTHYL)ETHYLENEDIAMINE; POTASSIUM IODIDE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; FLUORESCENCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; MICROENVIRONMENT; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 21844473805     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20503     Document Type: Article

References (57)

1. Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS, Lindgren FT. 1988. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 263:6249-6258.
2. Aleshkov SB, Abraham C, Zannis VI. 1997. Interaction of nascent apoE2, apoE3, and apoE4 isoforms expressed in mammalian cells with amyloid peptide â(1-40): relevance to Alzheimer's disease. Biochemistry 36:10571-10580.
3. Aleshkov SB, Li X, Lavrentiadou SN, Zannis VI. 1999. Contribution of cysteine 158, the glycosylation site threonine 194, the amino- and carboxy-terminal domains of apolipoprotein E in the binding to amyloid peptide β(1-40). Biochemistry 38:8918-8925.
4. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman C, Delong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. 1999. Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238.
5. Bentley NM, Ladu MJ, Rajan C, Getz GS, Reardon CA. 2002. Apolipoprotein E structural requirements for the formation of SDS-stable complexes with β-amyloid-(1-40): the role of salt bridges. Biochemistry 366:273-279.
6. -/- mice: isoform-specific effects on neurodegeneration. J Neurosci 19:4867-4880.
7. Chan W, Fornwald J, Brawner M, Wetzel R. 1996. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide Aβs. Biochemistry 35:7123-7130.
8. Choy N, Raussens V, Narayanaswami V. 2003. Inter molecular coiled-coil formation in human apolipoprotein E C-terminal domain. J Mol Biol 334:527-539.
9. Crutcher KA. 2004. Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease. J Mol Neurosci 23:181-188.
10. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. 2002. Oligomeric and fibrillar species of amyloid-b peptides differentially affect neuronal viability. J Biol Chem 277:32046-32053.
11. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. 1994. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 269:22358-22365.
12. Dong LM, Weisgraber KH. 1996. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271:19053-19057.
13. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. 1985. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA 82:203-207.
14. Fagan AM, Holtzman DM. 2000. Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-β deposition in vivo. Microsc Res Tech 50:297-304.
15. Fagan AM, Murphy BA, Patel SN, Kilbridge JF, Mobley WC, Bu G, Holtzman DM. 1998. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp Neurol 151: 314-325.
16. Fisher CA, Narayanaswami V, Ryan RO. 2000. The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E. J Biol Chem 275:33601-33606.
17. Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. 1997. Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. J Biol Chem 272:21037-21044.
18. Golabek AA, Kida E, Walus M, Perez C, Wisniewski T, Soto C. 2000. Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid β-peptide with the N-terminal, receptor binding domain of apolipoprotein E. Biophys J 779:1008-1015.
19. Golabek AA, Soto C, Vogel T, Wisniewski T. 1996. The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J Biol Chem 271:10602-10606.
20. Gylys KK, Fein JA, Tan AM, Cole GM. 2003. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-b protein into synaptic terminals. J Neurochem 84:1442-1451.
21. Hardy J, Gwinn-Hardy K. 1988. Genetic classification of primary neurodegenerative disease. Science 282:1075-1079.
22. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
23. Hyman BT, Strickland D, Rebeck GW. 2000. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol 57:646-650.
24. Ignatius MJ, Gebicke-Harter PJ, Skene JH, Schilling JW, Weisgraber KH, Mahley RW, Shooter EM. 1986. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 83:1125-1129.
25. Jarrett JT, Berger EP, Lansbury PT Jr. 1993. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697.
26. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. 1994. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 269:23403-23406.
27. LaDu MJ, Pederson TM, Frail DE, Reardon C, Getz GS, Falduto MT. 1995. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem 270:9039-9042.
28. Lakowicz JR. 1999. Energy transfer. In: Principles of Fluorescence Spectroscopy. New York: Kluwer Academic/Plenum Publishers p. 367-394.
29. Lambert MP, Barlow AK, Chromy BA, Edwards CA, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang P, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
30. Lins L, Thomas-Soumarmon A, Pillot T, Vandekerckhove J, Rosseneu, Brasseur R. 1999. Molecular determinants of the interaction between the C-terminal domain of Alzheimer's b-amyloid peptide and apolipoprotein E alpha-helices. J Neurochem 73:758-769.
31. Mahley RW, Huang Y. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10:207-217.
32. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller, EC, Otto A, Pfrieger FW. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357.
33. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. 1999. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274:6483-6492.
34. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. 2000. High-level neuronal expression of abeta-1-42 in wild-type human amyloid precursor protein transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
35. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166.
36. Narayanaswami V, Kim J, McNamee MG. 1993. Protein-lipid interactions and Torpedo californica nicotinic acetylcholine receptor function. 1. Spatial disposition of cysteine residues in the gamma subunit analyzed by fluorescence-quenching and energy-transfer measurements. Biochemistry 32:12413-12419.
37. Narayanaswami V, Ryan RO. 2000. Molecular basis of exchangeable apolipoprotein function. Biochim Biophys Acta 1483:15-36.
38. Narayanaswami V, Szeto S, Ryan RO. 2001. Lipid-association induced N- and C-terminal domain reorganization in human apolipoprotein E3. J Biol Chem 276:37853-37860.
39. Perugini MA, Schuck P, Howlett GJ. 2000. Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid. J Biol Chem 275:36758-36765.
40. Pillot T, Goethals M, Najib J, Labeur C, Lins L, Chambaz J, Brasseur R, Vandekerckhove J, Rosseneu M. 1999. β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J Neurochem 72:230-237.
41. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. 1987a. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262:14352-14360.
42. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. 1987b. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E containing lipoproteins. Biochim Biophys Acta 917:148-161.
43. Saito H, Lund-Katz S, Phillips MC. 2004. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res 43:350-380.
44. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmater WJ. 1994. Apolipoprotein E associates with β-amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860-869.
45. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. 1992. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 33:141-166.
46. Snipes GJ, McGuire CB, Norden JJ, Freeman JA. 1986. Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells. Proc Natl Acad Sci USA 83:1130-1134.
47. Strittmater WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993. Binding of human apolipoprotein E to synthetic amyloid β-peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 90:8098-8102.
48. Stryer L. 1978. Fluorescence energy transfer as a spectroscopic ruler. Annu Rev Biochem 47:819-846.
49. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J. 2000. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β-peptides. Biochemistry J 34:359-365.
50. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. 2002. Nature 416:535-539.
51. Weisgraber KH, Mahley RW. 1996. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10:1485-1494.
52. Weisgraber KH, Pitas RE, Mahley RW. 1994. Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr Opin Struct Biol 4:507-515.
53. Westerlund JA, Weisgraber KH. 1993. Discrete C-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem 268:15745-15750.
54. Wetterau JR, Aggerbeck LP, Rall SC Jr, Weisgraber KH. 1988. Human apolipoprotein E3 in solution I. Evidence for two structural domains. J Biol Chem 263:6240-6248.
55. Wilson C, Wardell MR, Weisgraber KH, Mahley RH, Agard DA. 1991. Three-dimensional structure of the LDL receptor binding domain of human apoE. Science 252:1817-1822.
56. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
57. Wisniewski T, Frangione B. 1992. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238.